

File No. 221203

Committee Item No. 3

Board Item No. \_\_\_\_\_

## COMMITTEE/BOARD OF SUPERVISORS

### AGENDA PACKET CONTENTS LIST

Committee: Budget and Finance Committee Date January 25, 2023

Board of Supervisors Meeting Date \_\_\_\_\_

#### Cmte Board

- Motion
- Resolution
- Ordinance
- Legislative Digest
- Budget and Legislative Analyst Report
- Youth Commission Report
- Introduction Form
- Department/Agency Cover Letter and/or Report
- MOU
- Grant Information Form
- Grant Budget
- Subcontract Budget
- Contract/Agreement
- Form 126 – Ethics Commission
- Award Letter
- Application
- Public Correspondence

#### OTHER (Use back side if additional space is needed)

<input type="checkbox"/>	<input type="checkbox"/>	_____
<input type="checkbox"/>	<input type="checkbox"/>	_____
<input type="checkbox"/>	<input type="checkbox"/>	_____
<input type="checkbox"/>	<input type="checkbox"/>	_____
<input type="checkbox"/>	<input type="checkbox"/>	_____
<input type="checkbox"/>	<input type="checkbox"/>	_____
<input type="checkbox"/>	<input type="checkbox"/>	_____
<input type="checkbox"/>	<input type="checkbox"/>	_____
<input type="checkbox"/>	<input type="checkbox"/>	_____
<input type="checkbox"/>	<input type="checkbox"/>	_____

Completed by: Brent Jalipa Date January 19, 2023

Completed by: Brent Jalipa Date \_\_\_\_\_

1 [Accept and Expend Grant - Retroactive - National Institutes of Health - Brief Longitudinal  
2 Incident Sentinel Surveillance (BLISS) to End the HIV Epidemic Among Persons Who Inject  
3 Drugs (PWID) - \$178,137]

4 **Resolution retroactively authorizing the Department of Public Health to accept and**  
5 **expend a grant in the amount of \$178,137 from the National Institutes of Health for**  
6 **participation in a program, entitled “Brief Longitudinal Incident Sentinel Surveillance**  
7 **(BLISS) to End the Human Immunodeficiency Virus (HIV) Epidemic among Persons**  
8 **Who Inject Drugs (PWID),” for the period of August 15, 2022, through July 31, 2023.**  
9

10 WHEREAS, The National Institutes of Health (NIH) has agreed to fund the Department  
11 of Public Health (DPH) in the amount of \$178,137 for participation in a program, entitled  
12 ““Brief Longitudinal Incident Sentinel Surveillance (BLISS) to End the Human  
13 Immunodeficiency Virus Epidemic among Persons Who Inject Drugs (PWID),” for the period  
14 of August 15, 2022, through July 31, 2023; and

15 WHEREAS, Although San Francisco appears on track to achieve zero new Human  
16 Immunodeficiency Virus (HIV) infections within the next few years, the trajectory among  
17 people who inject drugs (PWID) lags behind; and

18 WHEREAS, To end the HIV epidemic and mitigate other health disparities for PWID,  
19 data collection systems need to be more rapid, representative, and responsive to this  
20 population at high risk; and

21 WHEREAS, We therefore propose to create a new epidemiological data collection  
22 system for PWID in Alameda and San Francisco counties called Brief Longitudinal Incident  
23 Sentinel Surveillance (BLISS); and  
24  
25

1           WHEREAS, We will recruit 600 PWID (300 each in county) using a novel venue-  
2 based/peer-referral hybrid method called Starfish Sampling to accrue a cohort and follow  
3 them longitudinally; and

4           WHEREAS, The grant does not require an Annual Salary Ordinance Amendment; and

5           WHEREAS, A request for retroactive approval is being sought because DPH received  
6 the award letter on August 22, 2022, for a project start date of August 15, 2022; and

7           WHEREAS, The grant budget includes a provision for indirect costs in the amount of  
8 \$3,363; now, therefore, be it

9           RESOLVED, That DPH is hereby authorized to retroactively accept and expend a grant  
10 in the amount of \$178,137 from the NIH; and, be it

11           FURTHER RESOLVED, That DPH is hereby authorized to retroactively accept and  
12 expend the grant funds pursuant to Administrative Code, Section 10.170-1; and, be it

13           FURTHER RESOLVED, That the Director of Health is authorized to enter into the  
14 Agreement on behalf of the City.

15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

1 Recommended:

Approved: /s/\_\_\_\_\_

2

Mayor

3 /s/\_\_\_\_\_

4 Dr. Grant Colfax

Approved: /s/\_\_\_\_\_

5 Director of Health

Controller

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

**File Number:** 221203  
(Provided by Clerk of Board of Supervisors)

**Grant Resolution Information Form**  
(Effective July 2011)

Purpose: Accompanies proposed Board of Supervisors resolutions authorizing a Department to accept and expend grant funds.

The following describes the grant referred to in the accompanying resolution:

1. Grant Title: **Brief Longitudinal Incident Sentinel Surveillance (BLISS) to End the HIV Epidemic among Persons Who Inject Drugs (PWID)**
2. Department: **Department of Public Health  
Center of Public Health Research**
3. Contact Person: **William McFarland** Telephone: **415-437-6251**
4. Grant Approval Status (check one):  
 Approved by funding agency                       Not yet approved
5. Amount of Grant Funding Approved or Applied for: **\$178,137**
- 6a. Matching Funds Required: **\$0**  
b. Source(s) of matching funds (if applicable): **N.A.**
- 7a. Grant Source Agency: **National Institutes of Health (NIH)**  
b. Grant Pass-Through Agency (if applicable): **N.A.**
8. Proposed Grant Project Summary:

**The endgame for eliminating HIV will become increasingly difficult as transmission persists in populations who are the most marginalized from society, the hardest to reach with prevention programs, and the most challenging to include in epidemiological studies. Although San Francisco appears on track to achieve zero new HIV infections within the next few years, the trajectory among people who inject drugs (PWID) lags behind. The slower rate of decrease in HIV among PWID may be due to lower levels of awareness and uptake of pre-exposure prophylaxis (PrEP). Meanwhile, neighboring Alameda County (home to Oakland) has seen little decrease in the HIV epidemic, and outbreaks occur among PWID who are Black/African American or experiencing homelessness. In addition to HIV, PWID in the US are experiencing a surge in deaths due opioid overdose. To end the HIV epidemic and mitigate other health disparities for PWID, data collection systems need to be more rapid, representative, and responsive to this population at high risk. We therefore propose to create a new epidemiological data collection system for PWID in Alameda and San Francisco counties called Brief Longitudinal Incident Sentinel Surveillance (BLISS). We will recruit 600 PWID (300 each in county) using a novel venue-based / peer-referral hybrid method called Starfish Sampling to accrue a cohort and follow them longitudinally. Following HIV testing and a baseline questionnaire, participants will be enlisted to provide monthly brief responses to 11 sentinel events of high significance to the HIV and substance use epidemics (e.g., PrEP uptake or discontinuation, harm reduction program utilization, overdose experiences). Monthly data will be collected through smart phone and online technologies with in-person options as back up. Selected sentinel events will trigger “deeper dive” data collection through ecological momentary assessments (EMAs). The sample size is geared to detect events**

**occurring at low rates in the community as early warning signals and to obtain sufficient longitudinal data to assess causal factors for HIV risk and preventive behaviors, particularly barriers and facilitators to PrEP use and adherence. BLISS data will help identify and avert outbreaks, micro-target interventions, prioritize those at highest risk, fill unmet care and prevention needs, and end the HIV epidemic.**

9. Grant Project Schedule, as allowed in approval documents, or as proposed:

Start-Date: **08/15/2022**

End-Date: **07/31/2023**

10a. Amount budgeted for contractual services: **\$161,321**

b. Will contractual services be put out to bid? **No**

c. If so, will contract services help to further the goals of the Department's Local Business Enterprise (LBE) requirements? **N.A.**

d. Is this likely to be a one-time or ongoing request for contracting out? **On-going**

11a. Does the budget include indirect costs?  Yes  No

b1. If yes, how much? **\$3,363**

b2. How was the amount calculated? **25% of total personnel costs**

c1. If no, why are indirect costs not included? **N.A.**

Not allowed by granting agency

To maximize use of grant funds on direct services

Other (please explain):

c2. If no indirect costs are included, what would have been the indirect costs? **N.A.**

12. Any other significant grant requirements or comments:

**We respectfully request for approval to accept and expend these funds retroactive to August 15, 2022. The Department received the award on August 22, 2022.**

**This grant does not require an ASO amendment and partially reimburses the Department for one position: one Supervising Physician Specialist (Job Class #2233) at 0.05 FTE during the period of August 15, 2022, through July 31, 2023. The AL # for this grant is 93.855.**

**Proposal ID: CTR00003125  
Version ID: V101  
Department ID: 162646  
Project Description: HD HIV PD178 2223 BLISS  
Project ID: 10039291  
Activity ID: 0001**

**\*\*Disability Access Checklist\*\*\*(Department must forward a copy of all completed Grant Information Forms to the Mayor’s Office of Disability)**

13. This Grant is intended for activities at (check all that apply):

- |  |   |  |
|--|---|--|
| <input checked="" type="checkbox"/> Existing Site(s) | <input type="checkbox"/> Existing Structure(s)      | <input type="checkbox"/> Existing Program(s) or Service(s) |
| <input type="checkbox"/> Rehabilitated Site(s)       | <input type="checkbox"/> Rehabilitated Structure(s) | <input type="checkbox"/> New Program(s) or Service(s)      |
| <input type="checkbox"/> New Site(s)                 | <input type="checkbox"/> New Structure(s)           |  |

14. The Departmental ADA Coordinator or the Mayor's Office on Disability have reviewed the proposal and concluded that the project as proposed will be in compliance with the Americans with Disabilities Act and all other Federal, State and local disability rights laws and regulations and will allow the full inclusion of persons with disabilities. These requirements include, but are not limited to:

1. Having staff trained in how to provide reasonable modifications in policies, practices and procedures;
2. Having auxiliary aids and services available in a timely manner in order to ensure communication access;
3. Ensuring that any service areas and related facilities open to the public are architecturally accessible and have been inspected and approved by the DPW Access Compliance Officer or the Mayor’s Office on Disability Compliance Officers.

If such access would be technically infeasible, this is described in the comments section below:

Comments:

Departmental ADA Coordinator or Mayor’s Office of Disability Reviewer:

Toni Rucker, PhD  
(Name)

DPH ADA Coordinator  
(Title)

Date Reviewed: 10/31/2022 | 10:36 AM PDT

DocuSigned by:  
Toni Rucker  
784282F5331F44D...  
(Signature Required)

Department Head or Designee Approval of Grant Information Form:

Dr. Grant Colfax  
(Name)

Director of Health  
(Title)

Date Reviewed: 11/9/2022 | 4:15 PM PST

DocuSigned by:  
Greg Wagner  
20527524752646F...  
(Signature Required)

Greg wagner, COO for

Center for Public Health Research  
 Brief Longitudinal Incident Sentinel Surveillance (BLISS) DUNS #1037173360000  
 Year 1: Aug 15, 2022 to July 31, 2023  
 Budget Summary

**A. PERSONNEL**

**B. MANDATORY FRINGE**

1. 0.05 Sr. Supervising Physician Specialist: Willi McFarland, MD, PHD, MPH&TM

Annual Salary \$199,300 @ 0.05 FTE for 12 months = \$9,965

Mandatory Fringe Benefits @ 35% = \$3,488 \$13,453

As Principal Investigator for the NHBS this position has primary responsibility for planning, developing, directing, and evaluating all scientific aspects of the study. This position is the primary liaison with the CDC. This position develops survey protocols, policies, procedures and instruments. This position directly supervises one project director and indirectly supervises Research Assistants. This position works closely with CDC study epidemiologists.

<b>Total Salaries</b>	<b>\$9,965</b>
<b>Total Fringe</b>	<b>\$3,488</b>
<b>TOTAL PERSONNEL:</b>	<b>\$13,453</b>

**C. TRAVEL** **\$0**

**D. EQUIPMENT** **\$0**

**E. MATERIALS AND SUPPLIES** **\$0**

**F. CONTRACTUAL** **\$161,321**

Contractor	Amount
Heluna Health	\$ 117,623
Alameda County Public Health Dept	\$ 26,535
UCSF	\$ 17,163

**G. OTHER** **\$0**

**TOTAL DIRECT EXPENSES: \$174,774**



<b>H.     INDIRECT COSTS (25% of total personnel)</b>	<b>\$3,363</b>
<b>          TOTAL BUDGET FOR YEAR 2022:</b>	<b>\$178,137</b>

**BUDGET JUSTIFICATION PAGE  
MODULAR RESEARCH GRANT APPLICATION**

**Consortium**

Consortium with **Heluna Health (Yr 1 - 117,623)**

PHFE will provide the staffing for formative assessment and survey data collection. They have demonstrated expertise in this area and have an established relationship with the AIDS Office

**Erin Wilson (Meek), DrPH Co-Investigator**, (effort = 0.6 Cal Mos) is a Senior Research Scientist at the SFPDPH in the Center for Public Health Research and Assistant Professor at the University of California San Francisco in the Department of Epidemiology and Biostatistics. Dr. Wilson has over 10 years of experience working with and conducting research with adult trans women, trans men, and youth. Her research focuses on identifying stigma-related risk factors for HIV infection. She also focuses on describing, and ultimately intervening to reduce HIV-associated health disparities with HIV prevention interventions including pre-exposure prophylaxis, behavioral interventions, peer health navigation, and combination prevention strategies. Dr. Wilson is currently PI of two interventions to increase engagement in HIV care – one among young people in San Francisco and another study focused on trans women of color. She is PI of a study to increase uptake of PrEP among trans women and PI of two prospective social epidemiological studies associated HIV risk among adult and young trans women in the U.S. and globally. Dr. Wilson is currently launching a study of trans women and their sexual partners, an anti-stigma study of trans women in Nepal, an anti-stigma reduction intervention among providers who provide care to trans women in Brazil, and a HIV testing intervention with young trans women in Brazil. She was PI of the first longitudinal social and epidemiological NIMH-funded study of young trans women ages 16-24 and the first HIV surveillance study of trans men in San Francisco. Dr. Wilson will serve as Co-Investigator for the proposed study

**Sean Arayasirikul, PhD Co-Investigator**, (effort = 0.6 Cal Mos) is a medical sociologist, Assistant Professor in Pediatrics at the University of California, San Francisco (UCSF) and Senior Research Scientist at SFPDPH's Center for Public Health Research. Dr. Arayasirikul's mixed methods, intersectional research seeks to understand the social etiology of HIV acquisition, specifically how minority statuses and identities, discrimination and violence exacerbate health disparities. He brings expertise in examining the role of social action theory dimensions, including contextual influences and self-changes processes on health outcomes. His work is at the intersection of developing new behavioral HIV prevention interventions using mobile health (mHealth) technologies and the implementation science of mHealth interventions in clinical and public health settings. His research also explores means to disrupt intersectional stigma and discrimination to address negative health outcomes among marginalized populations including people who use drugs and youth. Dr. Arayasirikul will serve as Co-Investigator for the proposed study.

**HELUNA HEALTH - Other Personnel**

**Caitlin Turner, MPH, PhD Student , Data Manager**, (effort = 0.6 Cal Mos) is a Social Epidemiologist and PhD student in Epidemiology and Translational Sciences at UCSF. She has worked as a data manager on a number of HIV prevention studies at SFPDPH's Center for Public Health Research for over 5 years. As Data Manager, she will be responsible for developing the study databases, programming and testing data collection instruments, establishing data cleaning queries, conducting analyses, and contribute to manuscript writing and dissemination activities in collaboration with the MPIs.

**To Be Hired, Research Assistant**. (effort 2.4Cal Mos) A Research Assistant will be hired through Heluna Health and will report directly to the Investigative Team. The Research Assistant will support study recruitment, retention and data collection activities.

**To Be Hired, Research Assistant.** (effort 2.4Cal Mos) A Research Assistant will be hired through Heluna Health and will report directly to the Investigative Team. The Research Assistant will support study recruitment, retention and data collection activities.

**To Be Hired, Research Assistant.** (effort 2.4Cal Mos) A Research Assistant will be hired through Heluna Health and will report directly to the Investigative Team. The Research Assistant will support study recruitment, retention and data collection activities.

## **RESEARCH DEVELOPMENT SUPPORT**

**General Supplies, Years 1, (\$3,000):** Costs associated with implementing BLISS during the project period. Required supplies will include but are not limited to HIV testing supplies, tablets, binders, tabs, dividers, binder storage cabinets with locking mechanism, folders, printer cartridges, computer paper, labels, etc. There is also a need for general supplies such as envelopes, file folders/dividers, labels, memo pads, post-its, pencils, pens, staples, paper clips, writing pads, business cards, research file folders, etc. The costs for each year are as follows:

**Participant Stipends, Years 1, (\$23,500):** Participants enrolled into our longitudinal cohort sample (N=600) will complete baseline, 6-month, 12-month and 18-month study visits. For each visit, they will complete a survey interview (\$50), HIV/HCV testing and HCV RNA testing (\$25), hair testing (\$25) for a total of \$100USD for each study visit. Participants will be paid for peer referrals (\$10/referral for up to 5 referrals for a total of \$50).

**Indirect -** Costs for administrative support, calculated at 12.8% of modified total direct costs (MTDC).

**BUDGET JUSTIFICATION PAGE  
MODULAR RESEARCH GRANT APPLICATION**

**Consortium**

Consortium with **Alameda County Public Health Department (Yr 1- 26,535)**

**Neena Murgai, PhD, MPH, Co-Investigator** (0.60 calendar months in Years 1-2, and 1.20 calendar months in Years 3-5) is the Director of the HIV Epidemiology and Surveillance Unit at ACPHD. As Co-Principal Investigator for this grant, she has primary responsibility for leading and overseeing all activities related to the implementation of the NHBS cycle among people who inject drugs (PWID) and assessing the feasibility of the regional virtual PWID cohort for ACPHD. This includes developing collaborations with local, state, and federal stakeholders; and overseeing all formative and operational activities to conduct the NHBS in Alameda County. She will participate in regular planning meetings; oversee the ACPHD epidemiologists involved in case surveillance analysis and data management; and oversee the NHBS lead for ACPHD. She will collaborate closely with her SFDPH counterparts on all aspects of NHBS implementation and joint analyses across the two counties.

**Other Personnel**

**TBD, Project Coordinator**, NHBS (1.2 calendar months in Years 1-5) will lead NHBS planning and implementation activities in the HIV Epidemiology and Surveillance Unit at ACPHD. He/she will lead field operations to conduct the NHBS PWID cycle in Alameda County. He/she will participate in regular planning and team meetings; assist in developing collaborations with local, state, and federal stakeholders; lead formative assessment activities; and supervise research assistants conducting data collection. He/she will collaborate closely with SFDPH counterparts on all aspects of NHBS implementation.

**TBD, Data Manager**, NHBS (0.60 calendar months in Years 1-5) will lead NHBS data management activities in the HIV Epidemiology and Surveillance Unit at ACPHD. He/she will participate in regular planning and team meetings; develop and maintain data systems to support NHBS operations and data collection; implement NHBS data quality assurance protocols; and process and submit NHBS data to CDC. He/she will collaborate closely with SFDPH counterparts on all aspects of NHBS data management.

**BUDGET JUSTIFICATION PAGE  
MODULAR RESEARCH GRANT APPLICATION**

**Consortium**

Consortium with **University of San Francisco (Yr 1 - 17,163)**

UCSF will provide support for the work of Dr. Glenn-Milo Santos on the proposed project.

**Dr. Glenn Milo-Santos, PhD, MPH– UCSF Co-Investigator (0.6 Calendar Months for Year 1 through Year 5; salary support requested):** Dr. Santos will work closely with PI Dr. McFarland to advance the proposed specific aims. Dr. Santos has participated in the execution and conduct of 9 NIH-funded intervention trials among people who use drugs, as well as a CDC-funded behavioral study for substance-users. Dr. Santos is the PI of four NIH-funded studies evaluating the efficacy of combination interventions (pharmacologic agents with counseling modalities) among substance-using and alcohol-drinking individuals at high-risk for HIV, and PI of a 5-year NIDA funded supplement evaluating changes substance-use patterns using biomarkers. Dr. Santos was the lead author of a narrative review of interventions for alcohol and substance use, published in AIDS and Behavior, and he was the primary analyst in the first systematic review and meta-analysis conducted on the efficacy of behavioral interventions for amphetamine-group substances, published in The Lancet. Dr. Santos has led numerous analyses and manuscripts; he has co-authored over 100 peer-reviewed articles on the results of pharmacologic trials, predictors of medication adherence, social networks, substance use patterns, and risk-taking behaviors of people who use drugs. He was also part of the editorial board for the United Nations Office of Drug and Crime’s Treatment Guidelines on Stimulant Use and HIV. In addition, he has experience in the safety and monitoring of clinical trials as a member of the UCLA Data Safety Monitoring Board (DSMB) for Addiction Medicine.

For the proposed study, Dr. Santos will bring his considerable expertise in substance use research and research with PWID to this project. Dr. Santos will also oversee in the development of the data collection instruments to monitor and evaluate study outcomes and measures, including development of the ACASI instrument. Dr. Santos will work closely with the Study Coordinator to update the study protocol for proposed activities and ensure adherence to the protocol and integrity of all data collected. He will also contribute to the planning and execution of statistical analyses for the study’s specific aims and exploratory aims. Dr. Santos will also play an active role in disseminating data and study findings by preparing scientific abstracts, manuscripts, and annual reports.

**C. Equipment**

None

**D. Travel**

None

**E. Participant/Trainee Support Costs**

None.

**F. Other Direct Costs**

**UCSF Data Network Recharge (Y1-Y5: \$2,130):**

The data network services recharge or data network recharge is a vital component of the University’s Enterprise Network Services (ENS), which provides funding for critical equipment in support of UCSF’s

electronic information flow. Per agreement signed January 24, 2008 with The Department of Health & Human Services (DHHS), Division of Cost Allocation, (cognizant agency to the University), the University does not disclose ENS costs as F&A pool costs and can charge for ENS costs as direct costs. This cost totals \$426 per year for each year of the grant.

#### **H. INDIRECT COSTS**

University-wide flat indirect rate charged to sponsored projects with DPH at 12% of total direct costs.



Recipient Information	Federal Award Information														
<p><b>1. Recipient Name</b>            CITY &amp; COUNTY OF SAN FRANCISCO            101 GROVE ST             SAN FRANCISCO, 94102</p> <p><b>2. Congressional District of Recipient</b>            12</p> <p><b>3. Payment System Identifier (ID)</b>            1946000417A8</p> <p><b>4. Employer Identification Number (EIN)</b>            946000417</p> <p><b>5. Data Universal Numbering System (DUNS)</b>            103717336</p> <p><b>6. Recipient's Unique Entity Identifier</b>            DCTNHRGU1K75</p> <p><b>7. Project Director or Principal Investigator</b>            William McFarland, MD            Professor            willi.mcfarland@sfdph.org            415-554-9000</p> <p><b>8. Authorized Official</b>            Willi McFarland            willi.mcfarland@sfdph.org            415-554-9016</p>	<p><b>11. Award Number</b>            1R01AI169635-01</p> <p><b>12. Unique Federal Award Identification Number (FAIN)</b>            R01AI169635</p> <p><b>13. Statutory Authority</b>            42 USC 241 42 CFR 52</p> <p><b>14. Federal Award Project Title</b>            Brief Longitudinal Incident Sentinel Surveillance (BLISS) to End the HIV Epidemic among Persons Who Inject Drugs (PWID)</p> <p><b>15. Assistance Listing Number</b>            93.855</p> <p><b>16. Assistance Listing Program Title</b>            Allergy and Infectious Diseases Research</p> <p><b>17. Award Action Type</b>            New Competing</p> <p><b>18. Is the Award R&amp;D?</b>            Yes</p>														
<p><b>Federal Agency Information</b></p> <p><b>9. Awarding Agency Contact Information</b>            Nicole A Guidetti            Grants Management Program            NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES            nicole.guidetti@nih.gov            301-761-6934</p> <p><b>10. Program Official Contact Information</b>            Gerald B. Sharp            Program Officer            NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES            gsharp@niaid.nih.gov            240-627-3217</p>	<p><b>19. Budget Period Start Date 08-15-2022 – End Date 07-31-2023</b></p> <table border="1"> <tr> <td><b>20. Total Amount of Federal Funds Obligated by this Action</b></td> <td style="text-align: right;">\$178,137</td> </tr> <tr> <td>    20 a. Direct Cost Amount</td> <td style="text-align: right;">\$174,774</td> </tr> <tr> <td>    20 b. Indirect Cost Amount</td> <td style="text-align: right;">\$3,363</td> </tr> </table> <p><b>21. Authorized Carryover</b></p> <p><b>22. Offset</b></p> <table border="1"> <tr> <td><b>23. Total Amount of Federal Funds Obligated this budget period</b></td> <td style="text-align: right;">\$178,137</td> </tr> <tr> <td><b>24. Total Approved Cost Sharing or Matching, where applicable</b></td> <td style="text-align: right;">\$0</td> </tr> <tr> <td><b>25. Total Federal and Non-Federal Approved this Budget Period</b></td> <td style="text-align: right;">\$178,137</td> </tr> </table> <hr/> <p><b>26. Project Period Start Date 08-15-2022 – End Date 07-31-2027</b></p> <table border="1"> <tr> <td><b>27. Total Amount of the Federal Award including Approved Cost Sharing or Matching this Project Period</b></td> <td style="text-align: right;">\$178,137</td> </tr> </table> <p><b>28. Authorized Treatment of Program Income</b>            Additional Costs</p> <p><b>29. Grants Management Officer - Signature</b>            ANNIE NOEL Grimes</p>	<b>20. Total Amount of Federal Funds Obligated by this Action</b>	\$178,137	20 a. Direct Cost Amount	\$174,774	20 b. Indirect Cost Amount	\$3,363	<b>23. Total Amount of Federal Funds Obligated this budget period</b>	\$178,137	<b>24. Total Approved Cost Sharing or Matching, where applicable</b>	\$0	<b>25. Total Federal and Non-Federal Approved this Budget Period</b>	\$178,137	<b>27. Total Amount of the Federal Award including Approved Cost Sharing or Matching this Project Period</b>	\$178,137
<b>20. Total Amount of Federal Funds Obligated by this Action</b>	\$178,137														
20 a. Direct Cost Amount	\$174,774														
20 b. Indirect Cost Amount	\$3,363														
<b>23. Total Amount of Federal Funds Obligated this budget period</b>	\$178,137														
<b>24. Total Approved Cost Sharing or Matching, where applicable</b>	\$0														
<b>25. Total Federal and Non-Federal Approved this Budget Period</b>	\$178,137														
<b>27. Total Amount of the Federal Award including Approved Cost Sharing or Matching this Project Period</b>	\$178,137														
<p><b>30. Remarks</b></p>	<p>Acceptance of this award, including the "Terms and Conditions," is acknowledged by the recipient when funds are drawn down or otherwise</p>														

---

requested from the grant payment system.





RESEARCH  
Department of Health and Human Services  
National Institutes of Health



NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

---

**SECTION I – AWARD DATA – 1R01AI169635-01**

**Principal Investigator(s):**

William McFarland, MD

**Award e-mailed to:** barbara.garcia@sfdph.org

Dear Authorized Official:

The National Institutes of Health hereby awards a grant in the amount of \$178,137 (see "Award Calculation" in Section I and "Terms and Conditions" in Section III) to SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH in support of the above referenced project. This award is pursuant to the authority of 42 USC 241 42 CFR 52 and is subject to the requirements of this statute and regulation and of other referenced, incorporated or attached terms and conditions.

Acceptance of this award, including the "Terms and Conditions," is acknowledged by the recipient when funds are drawn down or otherwise requested from the grant payment system.

Each publication, press release, or other document about research supported by an NIH award must include an acknowledgment of NIH award support and a disclaimer such as "Research reported in this publication was supported by the National Institute Of Allergy And Infectious Diseases of the National Institutes of Health under Award Number R01AI169635. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health." Prior to issuing a press release concerning the outcome of this research, please notify the NIH awarding IC in advance to allow for coordination.

Award recipients must promote objectivity in research by establishing standards that provide a reasonable expectation that the design, conduct and reporting of research funded under NIH awards will be free from bias resulting from an Investigator's Financial Conflict of Interest (FCOI), in accordance with the 2011 revised regulation at 42 CFR Part 50 Subpart F. The Institution shall submit all FCOI reports to the NIH through the eRA Commons FCOI Module. The regulation does not apply to Phase I Small Business Innovative Research (SBIR) and Small Business Technology Transfer (STTR) awards. Consult the NIH website <http://grants.nih.gov/grants/policy/coi/> for a link to the regulation and additional important information.

If you have any questions about this award, please direct questions to the Federal Agency contacts.

Sincerely yours,

ANNIE NOEL Grimes  
Grants Management Officer  
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

Additional information follows

---

**Cumulative Award Calculations for this Budget Period (U.S. Dollars)**

Federal Direct Costs	\$174,774
Federal F&A Costs	\$3,363
Approved Budget	\$178,137
Total Amount of Federal Funds Authorized (Federal Share)	\$178,137
<b>TOTAL FEDERAL AWARD AMOUNT</b>	<b>\$178,137</b>
<b>AMOUNT OF THIS ACTION (FEDERAL SHARE)</b>	<b>\$178,137</b>

SUMMARY TOTALS FOR ALL YEARS (for this Document Number)		
YR	THIS AWARD	CUMULATIVE TOTALS
1	\$178,137	\$178,137
2	\$205,679	\$205,679
3	\$235,470	\$235,470
4	\$235,470	\$235,470
5	\$208,096	\$208,096

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

**Fiscal Information:**

Payment System Identifier: 1946000417A8  
 Document Number: RAI169635A  
 PMS Account Type: P (Subaccount)  
 Fiscal Year: 2022

IC	CAN	2022	2023	2024	2025	2026
AI	8472297	\$178,137	\$205,679	\$235,470	\$235,470	\$208,096

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

**NIH Administrative Data:**

PCC: A27G / OC: 41021 / Released: Grimes, ANNIE 08-01-2022  
 Award Processed: 08/15/2022 12:03:52 AM

**SECTION II – PAYMENT/HOTLINE INFORMATION – 1R01AI169635-01**

For payment and HHS Office of Inspector General Hotline information, see the NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm>

**SECTION III – STANDARD TERMS AND CONDITIONS – 1R01AI169635-01**

This award is based on the application submitted to, and as approved by, NIH on the above-titled project and is subject to the terms and conditions incorporated either directly or by reference in the following:

- a. The grant program legislation and program regulation cited in this Notice of Award.
- b. Conditions on activities and expenditure of funds in other statutory requirements, such as those included in appropriations acts.
- c. 45 CFR Part 75.
- d. National Policy Requirements and all other requirements described in the NIH Grants Policy

- Statement, including addenda in effect as of the beginning date of the budget period.
- e. Federal Award Performance Goals: As required by the periodic report in the RPPR or in the final progress report when applicable.
  - f. This award notice, INCLUDING THE TERMS AND CONDITIONS CITED BELOW.

(See NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm> for certain references cited above.)

**Research and Development (R&D):** All awards issued by the National Institutes of Health (NIH) meet the definition of "Research and Development" at 45 CFR Part§ 75.2. As such, auditees should identify NIH awards as part of the R&D cluster on the Schedule of Expenditures of Federal Awards (SEFA). The auditor should test NIH awards for compliance as instructed in Part V, Clusters of Programs. NIH recognizes that some awards may have another classification for purposes of indirect costs. The auditor is not required to report the disconnect (i.e., the award is classified as R&D for Federal Audit Requirement purposes but non-research for indirect cost rate purposes), unless the auditee is charging indirect costs at a rate other than the rate(s) specified in the award document(s).

An unobligated balance may be carried over into the next budget period without Grants Management Officer prior approval.

This grant is subject to Streamlined Noncompeting Award Procedures (SNAP).

This award is subject to the requirements of 2 CFR Part 25 for institutions to obtain a unique entity identifier (UEI) and maintain an active registration in the System for Award Management (SAM). Should a consortium/subaward be issued under this award, a UEI requirement must be included. See <http://grants.nih.gov/grants/policy/awardconditions.htm> for the full NIH award term implementing this requirement and other additional information.

This award has been assigned the Federal Award Identification Number (FAIN) R01AI169635. Recipients must document the assigned FAIN on each consortium/subaward issued under this award.

Based on the project period start date of this project, this award is likely subject to the Transparency Act subaward and executive compensation reporting requirement of 2 CFR Part 170. There are conditions that may exclude this award; see <http://grants.nih.gov/grants/policy/awardconditions.htm> for additional award applicability information.

In accordance with P.L. 110-161, compliance with the NIH Public Access Policy is now mandatory. For more information, see NOT-OD-08-033 and the Public Access website: <http://publicaccess.nih.gov/>.

In accordance with the regulatory requirements provided at 45 CFR 75.113 and Appendix XII to 45 CFR Part 75, recipients that have currently active Federal grants, cooperative agreements, and procurement contracts with cumulative total value greater than \$10,000,000 must report and maintain information in the System for Award Management (SAM) about civil, criminal, and administrative proceedings in connection with the award or performance of a Federal award that reached final disposition within the most recent five-year period. The recipient must also make semiannual disclosures regarding such proceedings. Proceedings information will be made publicly available in the designated integrity and performance system (currently the Federal Awardee Performance and Integrity Information System (FAPIIS)). Full reporting requirements and procedures are found in Appendix XII to 45 CFR Part 75. This term does not apply to NIH fellowships.

**Treatment of Program Income:**

Additional Costs

**SECTION IV – AI SPECIFIC AWARD CONDITIONS – 1R01AI169635-01**

Clinical Trial Indicator: No

This award does not support any NIH-defined Clinical Trials. See the NIH Grants Policy Statement Section 1.2 for NIH definition of Clinical Trial.

The budget period anniversary start date for future year(s) will be **August 1**.

\*\*\*\*\*

In accordance with the NIAID Financial Management Plan, NIAID does not provide funds for inflationary increases. See: <https://www.niaid.nih.gov/grants-contracts/financial-management-plan>.

\*\*\*\*\*

REMINDER: This grant is funded for HIV/AIDS research. Per the NIH Revitalization Act of 1993, funds are restricted for HIV/AIDS research and cannot be re-budgeted for other purposes.

\*\*\*\*\*

This is a Modular Award without direct cost categorical breakdowns in accordance with the guidelines published in the NIH Grants Policy Statement, see [https://grants.nih.gov/grants/policy/nihgps/HTML5/section\\_13/13.5\\_post-award\\_administration.htm](https://grants.nih.gov/grants/policy/nihgps/HTML5/section_13/13.5_post-award_administration.htm). Recipients are required to allocate and account for costs related to this award by category within their institutional accounting system in accordance with applicable cost principles.

\*\*\*\*\*

This Notice of Award (NoA) includes funds for **Heluna Health**.

This Notice of Award (NoA) includes funds for **University of California San Francisco**.

This Notice of Award (NoA) includes funds for **Alameda County Public Health Department**.

\*\*\*\*\*

This award includes human subject research studies and must conform to the DHHS policies for the [Protection of Human Subjects](#) research, which are a term and condition of award. Human subjects research is covered by the 2018 Common Rule, and may not be initiated until the associated protocols have received IRB approval as specified in [45 CFR 46](#). Failure to comply with the terms and conditions of award may result in the disallowance of costs and/or additional enforcement actions as outlined in Section 8.5 of the NIH Grants Policy Statement.

**SPREADSHEET SUMMARY**

**AWARD NUMBER:** 1R01AI169635-01

**INSTITUTION:** SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH

Budget	Year 1	Year 2	Year 3	Year 4	Year 5
TOTAL FEDERAL DC	\$174,774	\$202,316	\$232,107	\$232,107	\$204,733
TOTAL FEDERAL F&A	\$3,363	\$3,363	\$3,363	\$3,363	\$3,363
TOTAL COST	\$178,137	\$205,679	\$235,470	\$235,470	\$208,096

Facilities and Administrative	Year 1	Year 2	Year 3	Year 4	Year 5
-------------------------------	--------	--------	--------	--------	--------

Costs					
F&A Cost Rate 1	25%	25%	25%	25%	25%
F&A Cost Base 1	\$13,453	\$13,453	\$13,453	\$13,453	\$13,453
F&A Costs 1	\$3,363	\$3,363	\$3,363	\$3,363	\$3,363



London N. Breed  
Mayor

**TO:** Angela Calvillo, Clerk of the Board of Supervisors  
**FROM:** Dr. Grant Colfax  
Director of Health  
**DATE:** 11/30/2022  
**SUBJECT:** Grant Accept and Expend  
**GRANT TITLE:** Brief Longitudinal Incident Sentinel Surveillance (BLISS) to End the HIV Epidemic among Persons Who Inject Drugs (PWID) - \$178,137

---

Attached please find the original and 1 copy of each of the following:

- Proposed grant resolution, original signed by Department
- Grant information form, including disability checklist
- Budget and Budget Justification
- Grant application: Not Applicable. No application submitted.
- Agreement / Award Letter
- Other (Explain):

**Special Timeline Requirements:**

**Departmental representative to receive a copy of the adopted resolution:**

Name: Gregory Wong (greg.wong@sfdph.org) Phone: 554-2521

Interoffice Mail Address: Dept. of Public Health, 101 Grove St # 108

Certified copy required Yes

No